Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 6, 2009, Pages 735-740

  Hiremath, G S ^a   Cettomai, D ^a   Baynes, M ^a   Ratchford, J N ^a   Newsome, S ^a   Harrison, D ^a   Kerr, D ^a   Greenberg, B M ^a   Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

25 hydroxy vitamin D; Cholecalciferol; Demyelinating diseases; Ergocalciferol; MS; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; ERGOCALCIFEROL; NON PRESCRIPTION DRUG; VITAMIN D;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; PRESCRIPTION; RETROSPECTIVE STUDY; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; CHOLECALCIFEROL; DEMYELINATING DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; VITAMIN D DEFICIENCY; VITAMINS;

EID: 66149176929     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509102844     Document Type: Article

References (27)

1. Cosman, F, Nieves, J, Komar, L, et al. Fracture history and bone loss in patients with MS. Neurology 1998; 51: 1161-1165.
2. Sato, K, Suematsu, A, Okamoto, K, et al. Th17 functions as an osteoclastogenic helper T Cell subset that links T Cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682.
3. Arnson, Y, Amital, H, Shoenfeld, Y. Vitamin D and autoimmunity: New aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137-1142.
4. Gauzzi, MC, Purificato, C, Donato, K, et al. Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFNmediated monocyte differentiation into dendritic cells: Impairment of functional activities and chemotaxis. J Immunol 2005; 174: 270-276.
5. Adorini, L. Intervention in autoimmunity: The potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115-124.
6. Lyakh, LA, Sanford, M, Chekol, S, Young, HA, Roberts, AB. TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of humanmonocytes intoCD83+ dendritic cells. J Immunol 2005; 174: 2061-2070.
7. Subramaniam, N, Leong, GM, Cock, TA, et al. Cross-Talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001; 276: 15741-15746.
8. Aschenbrenner, JK, Sollinger, HW, Becker, BN, Hullett, DA. 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171-175.
9. Tone, Y, Furuuchi, K, Kojima, Y, Tykocinski, ML, Greene, MI, Tone, M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008; 9: 194-202.
10. Munger, KL, Levin, LI, Hollis, BW, Howard, NS, Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838.
11. Munger, KL, Zhang, SM, O'Reilly, E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65.
12. Goldberg, P, Fleming, MC, Picard, EH. Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986; 21: 193-200.
13. Wingerchuk, DM, Lesaux, J, Rice, GP, Kremenchutzky, M, Ebers, GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 1294-1296.
14. Polman, CH, Reingold, SC, Edan, G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
15. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499-505.
16. Holick, MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
17. Holick, MF. The vitamin D epidemic and its health consequences. J Nutr 2005; 135: 2739S-2748S.
18. Zadshir, A, Tareen, N, Pan, D, Norris, K, Martins, D. The prevalence of hypovitaminosis D among us adults: Data from the NHANES III. Ethn Dis 2005; 15: S5-97-101.
19. Chen, TC, Chimeh, F, Lu, Z, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007; 460: 213-217.
20. Nieves, J, Cosman, F, Herbert, J, Shen, V, Lindsay, R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687-1692.
21. Holick, MF, Biancuzzo, RM, Chen, TC, et al. Vitamin D2 is as effective as Vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-681.
22. Jodie, MB, Samantha, K, Reinhold, V, et al. Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis. American Academy of Neurology 2008; 70(Suppl. 1): 105.
23. Kimball, SM, Ursell, MR, O'Connor, P, Vieth, R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86: 645-651.
24. Hollis, BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317-322.
25. Vieth, R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 2004; 89-90: 575-579.
26. Tzartos, JS, Friese, MA, Craner, MJ, et al. Interleukin-17 production in central nervous system-infiltrating T Cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146-155.
27. Kebir, H, Kreymborg, K, Ifergan, I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-1175.